PT Kalbe Farma Tbk. (FRA:LCLA)

Germany flag Germany · Delayed Price · Currency is EUR
0.0445
-0.0050 (-10.10%)
At close: Feb 20, 2026
Market Cap2.40B -31.6%
Revenue (ttm)1.76B +7.0%
Net Income178.39M +13.4%
EPS0.00 +14.7%
Shares Outn/a
PE Ratio13.47
Forward PE12.60
Dividend0.00 (4.36%)
Ex-Dividend DateJun 4, 2025
Volumen/a
Average Volume26
Open0.0450
Previous Close0.0495
Day's Range0.0445 - 0.0450
52-Week Range0.0305 - 0.0900
Betan/a
RSI38.28
Earnings DateMar 27, 2026

About PT Kalbe Farma Tbk.

PT Kalbe Farma Tbk., together with its subsidiaries, develops, manufactures, and trades in pharmaceutical products in Indonesia. The company operates through Prescription Pharmaceuticals; Consumer Health; Nutritionals; and Distribution and Logistic segments. The company provides prescription/ethical; consumer health; nutritionals; distribution and logistics; health services; medical devices; biopharma; animal health; international business; and E-health products. It operates Mitrasana Clinics, a health care service. In addition, the company pro... [Read more]

Industry Pharmaceutical Preparations
Founded 1966
Employees 12,784
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol LCLA
Full Company Profile

Financial Performance

In 2024, PT Kalbe Farma Tbk.'s revenue was 32.63 trillion, an increase of 7.16% compared to the previous year's 30.45 trillion. Earnings were 3.24 trillion, an increase of 17.13%.

Financial numbers in IDR Financial Statements